Kymriah To Set Off Alarms As it Becomes Japan’s Most Expensive Drug?

While Japanese regulatory authorities have gone ahead and granted reimbursement to Kymriah under the national health insurance system, speculation seems to be building that the high price may reignite national public and political debate over the cost of innovative new therapies.

The Central Social Insurance Medical Council (Chuikyo), an advisory body to the Ministry of Health, Labour and Welfare, said the single-dose chimeric antigen receptor T cell (CAR-T)